the aid library

Filter

396

WHO guideline on control and elimination of human schistosomiasis
recommended

World Health Organization World Health Organization WHO (2022) CC

Schistosomiasis is a public health problem in tropical and subtropical regions of Africa, Asia, the Caribbean and South America. It is one of the neglected tropical diseases (NTDs) - a group of diseases and conditions that affect particularly low-income populations, worldwide. Last year, WHO laun ... more

Guidelines for the clinical management of severe illness from influenza virus infections

World Health Organization WHO (2022) C_WHO

The purpose of this document is to guide clinicians in the care of patients with or at risk of severe illness from influenza virus infection, including those caused by seasonal influenza viruses, pandemic influenza viruses and zoonotic (novel influe ... more

WHO recommendations on the management of diarrhoea and pneumonia in HIV-infected infants and children

World Health Organization (2010) C_WHO

To improve survival and quality of life among the 2.5 million children living with HIV, a comprehensive package of prevention, care and treatment is required. This package should include management of infections such as pneumonia, diarrhoea, malaria and ear infections, as well as common opportunisti ... more

Antibiotic Stewardship - From Principles to Practice / Ebook

British Society for Antimicrobial Chemotherapy BSAC (2019) C2

This book provides significantly expanded content and experience in relation to a broader stewardship context- for example, stewardship in specific populations, different countries as well as the role of different professions in stewardship to political and media engagement. We hope this book has so ... more

A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021
recommended

World Health Organization WHO (2021) C_WHO

WHO has developed a clinical case definition of post COVID-19 condition by Delphi methodology that includes 12 domains, available for use in all settings. This first version was developed by patients, researchers and others, representing all WHO regions, with the understanding that the definition ma ... more

Transforming the medical PPE ecosystem: Joint action can protect healthcare workers with effective and high-quality personal protective equipment

Global Fund (2021) CC

Access to medical personal protective equipment (PPE) is essential for routine healthcare delivery, and a critical tool for containing outbreaks, as well as preventing and responding to pandemics. It is one of our most effective tools against COVID-19, and an undervalued tool more generally in ... more

Soins cliniques pour les survivants de la maladie à virus Ebola: Guide provisoire
recommended

Organisation mondiale de la Santé (OMS) (2016) C_WHO

Ce document présente des recommandations sur les soins cliniques et le dépistage du virus chez les survivants de la maladie à virus Ebola. Il s'adresse principalement aux professionnels de santé qui dispensent des soins primaires aux personnes ayant survécu.
Table des matières
... more

WHO list of priority medical devices for cancer management

World Health Organization WHO (2017) C_WHO

This publication is based on the list of clinical interventions selected from clinical guidelines on prevention, screening, diagnosis, treatment, palliative care, monitoring and end of life care. This publication addresses medical devices for six types of cancer: breast, cervical, colorectal, leukem ... more

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for ... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Basic occupational safety and health for respiratory diseases

The Union (2021) C1

A desk guide for health facilities . It outlines a comprehensive approach to respiratory health, which health facilities can adapt and implement in resource-limited settings

Checklist for Antibiotic Prescribing in Dentistry

Centers for Disease Control and Prevention CDC (2019) C_CDC

Checklist for Antibiotic Prescribing in Dentistry - Fact Sheet

Update 66 – COVID-19 vaccine booster doses

World Health Organization WHO (2021) CC

September 2021

Information for Travellers to Madagascar

European Centre for Disease Prevention and Control (2017) C1

This information leaflet is for general informative purposes only. It can be used in its current form or further modified and adapted by responsible authorities in each country as a country-specific guidance.

Philippine Health Advisories

Department of Health, National Center for Health Promotion, National Center for Disease Prevention and Control (2012) C1

WHO/Europe and ECDC Monkeypox Surveillance Bulletin
recommended

World Health Organization WHO, Regional Office of Europe; European Center for Disease Control ECDC (2022) C_WHO

Here you can find the latest reports

Summary of WHO Position Paper on Diphtheria Vaccines, August 2017

World Health Organization WHO (2017) C_WHO

Guidelines on the Management of Sexually‐Transmitted Infections (STI) In Pregnancy

National Center for Disease Prevention and Control Department of Health, Philippines (2010) C1

Definition and categorization of the timing of mother-to-child transmission of SARS-CoV-2

World Health Organization WHO (2021) C_WHO

The WHO COVID-19 LENS (Living Evidence Synthesis) working group consolidated available evidence, based on rapid reviews of the literature and results of a living systematic review on pregnancy and COVID-19 (up to October 7, 2020), on potential mechanisms of vertical transmission of infectious pathog ... more

Challenges and advancements in the development of vaccines and therapies against Chagas disease

Pinazo, M.J.; E. Malchiodi, J.P. Ioset, (2024) CC

The Lancet Volume 5, Issue 10100972October 2024 Chagas Disease Serie 3

Common Skin Diseases In Africa: An Illustrated Guide
recommended

Colette van Hees and Ben Naafs (2004) C1